UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: July 2631, 2024

(Commission File No. 001-39308)

CALLIDITAS THERAPEUTICS AB

(Translation of registrant’s name into English)

Kungsbron 1, D5
SE-111 22
Stockholm, Sweden
(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Enclosed hereto ~~are~~is ~~copies~~a copy of ~~announcements~~an announcement published by Calliditas Therapeutics AB on July 2631, 2024.

The information contained in this Form 6-K, including Exhibit 99.1 and 99.2, is hereby incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-265881) and Form S-8 (File Nos. 333-240126 and 333-272594).

EXHIBIT INDEX

Exhibit		Description
99.1		Press Release dated July 2631, 2024
99.2		Press Release dated July 26, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CALLIDITAS THERAPEUTICS AB
Date: July 26, 2024	By:	/s/ Fredrik Johansson
Date: July 31, 2024	By:	/s/ Fredrik Johansson
		Fredrik Johansson
		Chief Financial Officer

Filing Compare · Calliditas Therapeutics AB